A Split-Face Study Assessing the Clinical Benefit, Tolerability and Subject Satisfaction of a Dermocosmetic in Subjects with Rosacea Associated with Erythema and Sensitive Skin

Figures & data

Table 1 Demographic and Baseline Data

Parameters	Values
Age (years)	48
Phototype (n, %)
II	12 (60%)
III	8 (40%)
Skin stinging test
M89	4.0±2.2
Standard care	4.1±1.9
Skin hydration (arbitrary units)
Corneometer
M89	42.7±10.8
Standard care	42.9±10.6
GPSB
M89	22.5±12.4
Standard care	22.7±13.5
TEWL (g/h m²)
Tewameter
M89	16.69±4.83
Standard care	17.29±3.38
GPSB
M89	12.0±9.6
Standard care	11.8±8.0
Clinical signs and symptoms (score 0 to 10)
Erythema	5.8±2.3
Desquamation	0.1±0.3
Number of papules/pustules	0.1±0.3
Tightness	2.9±3.0
Dryness	5.4±1.7
Burning	0±0
Itching	0±0
Stinging	0±0

Abbreviation: GPSB, GPSkin Barrier^®.

Figure 1 Skin hydration assessed with Corneometer and GPSkin^® at Day 0, 15 and 30. Mean skin hydration measured using the Corneometer CM 825^® had significantly improved from Day 0 at Day 15 and Day 30 in the M89 and the standard skin care group (*P<0.0001; **P<0.001). Mean skin hydration measured using GPSkin Barrier^® had significantly improved from Day 0 at Day 15 and Day 30 in the M89 group (***P<0.01; ****P<0.05), while there was no significant improvement observed, at any time points with the standard skin care.

Figure 2 Transepidermal water loss (TEWL) assessed with Tewameter and Corneometer at Day 0, 15 and 30. Mean TEWL assessed with the Tewameter had significantly reduced from Day 0 at Day 15 and Day 30 in the M89 group (*P<0.05, **P<0.01), while there was no significant improvement observed, at any time points with the standard skin care. There was no statistically significant difference observed when using the Corneometer.

Figure 3 Results for skin stinging test at Day 0, 15 and 30. Results from the skin stinging test showed that mean sum of scores had significantly reduced from Day 0 at both Day 15 and Day 30 time points in the M89 group (*P<0.01).

Figure 4 Subject satisfaction after 15 and 30 days of continued daily use of M89.